Core Outcome Sets (COS) related to pregnancy and childbirth: a systematic review.


Journal

BMC pregnancy and childbirth
ISSN: 1471-2393
Titre abrégé: BMC Pregnancy Childbirth
Pays: England
ID NLM: 100967799

Informations de publication

Date de publication:
09 Oct 2021
Historique:
received: 25 03 2021
accepted: 24 09 2021
entrez: 10 10 2021
pubmed: 11 10 2021
medline: 15 12 2021
Statut: epublish

Résumé

Systematic reviews often conclude low confidence in the results due to heterogeneity in the reported outcomes. A Core Outcome Set (COS) is an agreed standardised collection of outcomes for a specific area of health. The outcomes included in a COS are to be measured and summarized in clinical trials as well as systematic reviews to counteract this heterogeneity. The aim is to identify, compile and assess final and ongoing studies that are prioritizing outcomes in the area of pregnancy and childbirth. All studies which prioritized outcomes related to pregnancy and childbirth using consensus method, including Delphi surveys or consensus meetings were included. Searches were conducted in Ovid MEDLINE, EMBASE, PsycINFO, Academic Search Elite, CINAHL, SocINDEX and COMET databases up to June 2021. For all studies fulfilling the inclusion criteria, information regarding outcomes as well as population, method, and setting was extracted. In addition, reporting in the finalized studies was assessed using a modified version of the Core Outcome Set-STAndards for Reporting. In total, 27 finalized studies and 42 ongoing studies were assessed as relevant and were included. In the finalized studies, the number of outcomes included in the COS ranged from 6 to 51 with a median of 13 outcomes. The majority of the identified COS, both finalized as well as ongoing, were relating to physical complications during pregnancy. There is a growing number of Core Outcome Set studies related to pregnancy and childbirth. Although several of the finalized studies follow the proposed reporting, there are still some items that are not always clearly reported. Additionally, several of the identified COS contained a large number (n > 20) outcomes, something that possibly could hinder implementation. Therefore, there is a need to consider the number of outcomes which may be included in a COS to render it optimal for future research.

Sections du résumé

BACKGROUND BACKGROUND
Systematic reviews often conclude low confidence in the results due to heterogeneity in the reported outcomes. A Core Outcome Set (COS) is an agreed standardised collection of outcomes for a specific area of health. The outcomes included in a COS are to be measured and summarized in clinical trials as well as systematic reviews to counteract this heterogeneity.
AIM OBJECTIVE
The aim is to identify, compile and assess final and ongoing studies that are prioritizing outcomes in the area of pregnancy and childbirth.
METHODS METHODS
All studies which prioritized outcomes related to pregnancy and childbirth using consensus method, including Delphi surveys or consensus meetings were included. Searches were conducted in Ovid MEDLINE, EMBASE, PsycINFO, Academic Search Elite, CINAHL, SocINDEX and COMET databases up to June 2021. For all studies fulfilling the inclusion criteria, information regarding outcomes as well as population, method, and setting was extracted. In addition, reporting in the finalized studies was assessed using a modified version of the Core Outcome Set-STAndards for Reporting.
RESULTS RESULTS
In total, 27 finalized studies and 42 ongoing studies were assessed as relevant and were included. In the finalized studies, the number of outcomes included in the COS ranged from 6 to 51 with a median of 13 outcomes. The majority of the identified COS, both finalized as well as ongoing, were relating to physical complications during pregnancy.
CONCLUSION CONCLUSIONS
There is a growing number of Core Outcome Set studies related to pregnancy and childbirth. Although several of the finalized studies follow the proposed reporting, there are still some items that are not always clearly reported. Additionally, several of the identified COS contained a large number (n > 20) outcomes, something that possibly could hinder implementation. Therefore, there is a need to consider the number of outcomes which may be included in a COS to render it optimal for future research.

Identifiants

pubmed: 34627170
doi: 10.1186/s12884-021-04164-y
pii: 10.1186/s12884-021-04164-y
pmc: PMC8501579
doi:

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

691

Informations de copyright

© 2021. The Author(s).

Références

Trials. 2020 Mar 30;21(1):300
pubmed: 32228655
PLoS Med. 2017 Nov 16;14(11):e1002447
pubmed: 29145404
Ann Rheum Dis. 2021 Jan;80(1):49-56
pubmed: 33055080
J Womens Health (Larchmt). 2012 Sep;21(9):925-32
pubmed: 22747422
Trials. 2021 Feb 23;22(1):158
pubmed: 33622390
Ultrasound Obstet Gynecol. 2020 May;55(5):652-660
pubmed: 31273879
Ultrasound Obstet Gynecol. 2019 Aug;54(2):255-261
pubmed: 30520170
Trials. 2022 Apr 4;23(1):249
pubmed: 35379305
BJOG. 2017 Sep;124(10):1481-1489
pubmed: 28421657
Diabetologia. 2017 Jul;60(7):1190-1196
pubmed: 28409213
BJOG. 2016 Jan;123(2):190-8
pubmed: 26841002
BMJ Open. 2017 Nov 16;7(11):e018535
pubmed: 29150474
Trials. 2020 Aug 21;21(1):732
pubmed: 32825852
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Diabetologia. 2019 Nov;62(11):2007-2016
pubmed: 31273408
Int J Gynaecol Obstet. 2019 Nov;147(2):134-139
pubmed: 31571233
Trials. 2020 Dec 11;21(1):1017
pubmed: 33308263
J Clin Epidemiol. 2013 May;66(5):538-45
pubmed: 22995855
Obes Sci Pract. 2021 Feb 03;7(3):251-259
pubmed: 34123392
Am J Obstet Gynecol. 2019 Oct;221(4):339.e1-339.e10
pubmed: 31152710
Eur J Contracept Reprod Health Care. 2018 Dec;23(6):451-457
pubmed: 30600730
BJOG. 2021 Dec;128(13):2141-2149
pubmed: 34047454
Obstet Gynecol. 2016 Jan;127(1):49-58
pubmed: 26646133
PLoS Med. 2016 Oct 18;13(10):e1002148
pubmed: 27755541
BMC Pregnancy Childbirth. 2020 Jun 26;20(1):376
pubmed: 32591018
BMC Health Serv Res. 2018 Dec 11;18(1):953
pubmed: 30537958
Obstet Med. 2018 Sep;11(3):132-136
pubmed: 30214479
Pediatrics. 2020 Jul;146(1):
pubmed: 32493710
Pediatr Res. 2021 May;89(6):1380-1385
pubmed: 32927468
Aust N Z J Obstet Gynaecol. 2021 Oct;61(5):658-666
pubmed: 34060072
Trials. 2018 Nov 27;19(1):655
pubmed: 30482249
Birth. 2007 Jun;34(2):164-72
pubmed: 17542821
BJOG. 2020 Nov;127(12):1516-1526
pubmed: 32416644
BJOG. 2019 Jan;126(1):83-93
pubmed: 29920912
Hypertens Pregnancy. 2014 May;33(2):115-31
pubmed: 24303960
BMC Pregnancy Childbirth. 2021 Mar 25;21(1):251
pubmed: 33765964
BJOG. 2018 Nov;125(12):1612-1618
pubmed: 29770557
Diabetologia. 2020 Jun;63(6):1120-1127
pubmed: 32193573
BJOG. 2020 Jul;127(8):983-992
pubmed: 32056342
Syst Rev. 2016 Jan 20;5:11
pubmed: 26792080
Clin Exp Rheumatol. 2005 Sep-Oct;23(5 Suppl 39):S10-3
pubmed: 16273779
Am J Perinatol. 2020 Mar;37(4):436-452
pubmed: 30818401
BMJ Open. 2020 Jul 19;10(7):e034018
pubmed: 32690497
BJOG. 2018 Dec;125(13):1673-1680
pubmed: 29981523
BMC Med Res Methodol. 2017 Apr 19;17(1):61
pubmed: 28420339
BJOG. 2017 Mar;124(4):661-667
pubmed: 27860117
BMJ Open. 2018 Aug 5;8(8):e021619
pubmed: 30082354
Syst Rev. 2016 Dec 5;5(1):210
pubmed: 27919275
Trials. 2017 Jun 20;18(Suppl 3):280
pubmed: 28681707
Contraception. 2017 May;95(5):437-441
pubmed: 28065833
BMJ Open. 2020 Jul 19;10(7):e034017
pubmed: 32690496

Auteurs

Marie Österberg (M)

Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU), Stockholm, Sweden. Marie.Osterberg@sbu.se.

Christel Hellberg (C)

Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU), Stockholm, Sweden.

Ann Kristine Jonsson (AK)

Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU), Stockholm, Sweden.

Sara Fundell (S)

Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU), Stockholm, Sweden.

Frida Trönnberg (F)

Patient Representative, Linköping, Sweden.

Alkistis Skalkidou (A)

Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.

Maria Jonsson (M)

Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH